Loading...

Brigid Boland

TitleAssistant Adjunct Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
AddressUCSD Medical Center, MC0956, 9452 Medical Center Dr.
La Jolla CA 92037
Phone858-246-2353
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Advanced Fellowship2015UC San Diego
    Fellowship2013UC San Diego
    Residency2010UC San Diego Physician-Scientist Training Program
    MD2008UC San Francisco School of Medicine
    BS2003Yale University
    Collapse Awards and Honors
    UCSD2017  - 2019KL2
    CCFA2015  - 2018Career Development Award
    AGA2017Future Leader
    CCFA San Diego/Riverside 2017Top 50 in 50 years

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Identifying Biomarkers Predictive of Clinical and Endoscopic Response to Vedolizumab in Inflammatory Bowel Disease
    NIH 1KL2TR001444Jan 1, 2017
    Identifying Biomarkers Predictive of Clinical and Endoscopic Response to Vedolizumab in Inflammatory Bowel Disease
    CCFA Career Development AwardOct 1, 2015 - Sep 30, 2018

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Websites
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dulai PS, Boland B, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease. Gastroenterology. 2018 May 29. PMID: 29857091.
      View in: PubMed
    2. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland B, Singh S, Casteele NV, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 May 18. PMID: 29788240.
      View in: PubMed
    3. Klann JE, Kim SH, Remedios KA, He Z, Metz PJ, Lopez J, Tysl T, Olvera JG, Ablack JN, Cantor JM, Boland B, Yeo G, Zheng Y, Lu LF, Bui JD, Ginsberg MH, Petrich BG, Chang JT. Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance. J Immunol. 2018 Apr 27. PMID: 29703862.
      View in: PubMed
    4. Fumery M, Patel NS, Boland B, Dulai PS, Singh S, Sandborn WJ. Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 Apr 25. PMID: 29697797.
      View in: PubMed
    5. Park S, Evans E, Sandborn WJ, Boland B. Ustekinumab IV 6?mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. Am J Gastroenterol. 2018 Apr; 113(4):627-629. PMID: 29610516.
      View in: PubMed
    6. Singh S, George J, Boland B, Vande Casteele N, Sandborn WJ. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 Jan 23. PMID: 29370397.
      View in: PubMed
    7. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland B. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. PMID: 29345635.
      View in: PubMed
    8. Boland B, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. Am J Gastroenterol. 2017 Oct; 112(10):1621. PMID: 28978958.
      View in: PubMed
    9. Boland B, Vermeire S. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. Gastroenterol Clin North Am. 2017 Sep; 46(3):627-644. PMID: 28838419.
      View in: PubMed
    10. Boland B, Shergill A, Kaltenbach T. Endoscopic Surveillance in Long-standing Colitis. Curr Treat Options Gastroenterol. 2017 Sep; 15(3):429-439. PMID: 28803403.
      View in: PubMed
    11. Bertin S, Aoki-Nonaka Y, Lee J, de Jong PR, Kim P, Han T, Yu T, To K, Takahashi N, Boland B, Chang JT, Ho SB, Herdman S, Corr M, Franco A, Sharma S, Dong H, Akopian AN, Raz E. The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1. Gut. 2017 09; 66(9):1584-1596. PMID: 27325418.
      View in: PubMed
    12. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland B, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug; 111(8):1147-55. PMID: 27296941.
      View in: PubMed
    13. Boland B, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 05; 111(5):746-8. PMID: 27151126.
      View in: PubMed
    14. Dulai PS, Singh S, Casteele NV, Boland B, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. PMID: 26835982.
      View in: PubMed
    15. Boland B, Dulai PS, Chang M, Sandborn WJ, Levesque BG. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. PMID: 26618431.
      View in: PubMed
    16. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland B, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. PMID: 25731159; PMCID: PMC4447318.
    17. Boland B, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. PMID: 25667416; PMCID: PMC4355235.
    18. Boland B, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. PMID: 25545378; PMCID: PMC4404151.
    19. Boland B, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. PMID: 25110261; PMCID: PMC4129380.
    20. Boland B, Rivera-Nieves J, Gupta S. Lower endoscopy and prevention of colon cancer. Gastroenterology. 2014 Jul; 147(1):245-6. PMID: 24866428.
      View in: PubMed
    21. Zhang B, Copur-Dahi N, Kalmaz D, Boland B. Gastrointestinal manifestations of breast cancer metastasis. Dig Dis Sci. 2014 Sep; 59(9):2344-6. PMID: 24748230.
      View in: PubMed
    22. Pola S, Boland B, Lin GY, Kuo A, Sandborn WJ. Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. PMID: 24535249.
      View in: PubMed
    23. Boland B, Dong MH, Bettencourt R, Barrett-Connor E, Loomba R. Association of serum bilirubin with aging and mortality. J Clin Exp Hepatol. 2014 Mar; 4(1):1-7. PMID: 25328328; PMCID: PMC4017193.
    24. Boland B, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am. 2013 Dec; 42(4):809-32. PMID: 24286951.
      View in: PubMed
    25. Montandon M, Sahin-Hodoglugil NN, Bukusi E, Agot K, Boland B, Cohen CR. Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya. Sex Health. 2008 Dec; 5(4):339-46. PMID: 19061553.
      View in: PubMed
    26. Ndhlovu LC, Chapman JM, Jha AR, Snyder-Cappione JE, Pagán M, Leal FE, Boland B, Norris PJ, Rosenberg MG, Nixon DF. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS. 2008 May 11; 22(8):990-2. PMID: 18453860; PMCID: PMC2850608.
    27. Fonder MA, Sacco KA, Termine A, Boland B, Seyal AA, Dudas MM, Vessicchio JC, George TP. Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor antagonist. Biol Psychiatry. 2005 Apr 01; 57(7):802-8. PMID: 15820238.
      View in: PubMed